Barclays Maintains Equal-Weight on Quest Diagnostics, Raises Price Target to $154
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Stephanie Davis maintains an Equal-Weight rating on Quest Diagnostics (NYSE:DGX) and raises the price target from $144 to $154.
August 27, 2024 | 2:18 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Barclays has maintained its Equal-Weight rating on Quest Diagnostics while increasing the price target from $144 to $154, indicating a positive outlook.
The increase in price target from $144 to $154 by Barclays suggests a positive outlook for Quest Diagnostics, which could lead to a short-term increase in stock price. The maintained Equal-Weight rating indicates a balanced view, but the raised target shows confidence in potential growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100